Juan Jose Ruiz Treviño has been recognized with a 2026 Global Recognition Award for contributions that have reshaped the boundaries of reconstructive breast surgery, combining surgical innovation with measurable social impact to expand access to breast reconstruction for cancer patients worldwide, earning him distinction in the Innovation category.

Treviño’s work connects technical advancement with patient welfare, addressing one of the most persistent problems in reconstructive oncology: the gap between what modern surgery can offer and what patients can actually access. High procedure costs, elevated complication rates, and limited adoption of newer technologies have historically left thousands of women without adequate post-mastectomy care, and Treviño approached each of these barriers as a solvable clinical and systemic problem. His career has been shaped by the conviction that surgical excellence is meaningful only when it translates into outcomes patients can realistically achieve.

His central innovation has been the adoption and clinical development of poly-4-hydroxybutyrate (P4HB) mesh, commercially available as GalaFlex, as a tissue support system in aesthetic and reconstructive breast surgery, replacing traditional procedures that relied on acellular dermal matrices (ADMs) derived from cadaveric tissue. The costs associated with ADMs placed reconstruction out of reach for many patients and insurers, and Treviño’s technique offered a cost-effective alternative that reduced procedural expenses to a fraction of what ADM-based reconstruction had historically required. The outcome was not merely a technical substitution, as more insurance providers began approving coverage and more women gained access to reconstruction that would otherwise have been denied.

Surgical Precision and Patient Outcomes

The clinical results of Treviño’s approach have been significant and well-documented, particularly in the context of immediate breast reconstruction following mastectomy, where he combined P4HB mesh support with intraoperative angiography using indocyanine green. This combination enabled surgical teams to assess tissue perfusion in real time, thereby reducing rates of tissue necrosis and implant loss, which had previously represented major sources of post-operative complications. Patients undergoing one of the most physically and emotionally demanding procedures in oncologic treatment benefited from stronger reconstructive outcomes and a recovery experience that was meaningfully improved.

Treviño also participated in publishing the world’s first documented experience of immediate implant-based breast reconstruction using P4HB mesh in a series of more than fifty cases, which provided the scientific foundation necessary for wider clinical adoption. The documentation validated what had initially been a locally implemented technique, opening a path for surgical centers across other regions to replicate it with confidence. This publication marks a milestone in the formal integration of P4HB mesh into evidence-based reconstructive practice, contributing to a growing body of literature supporting the procedure’s safety and effectiveness.

Knowledge Transfer and Social Responsibility

Treviño’s reach extends well beyond his own operating room, as he has taught fellow plastic surgeons the tissue-support techniques central to his practice through workshops, symposia, and cadaveric model training programs. The methods he developed within his clinical setting have taken root in other institutions, extending their benefit to patients across multiple regions who might never have come under his direct care. The replication of his techniques through structured education reflects a deliberate effort to ensure that surgical advancement does not remain confined to a single practice or geography.

His commitment to accessibility has taken a direct form each year, when he organizes pro bono campaigns for women with limited financial resources who require post-mastectomy reconstruction, ensuring that financial barriers do not determine who receives dignified surgical care. The resistance he encountered within the medical community, along with initial skepticism toward new technologies, required that his work be backed by measurable clinical evidence rather than advocacy alone. The outcomes achieved, the reduction in complications, and the increased economic accessibility of reconstruction collectively made the case for these innovations more effective than any argument could have.

Final Words

Treviño’s nomination was evaluated under the Global Recognition Awards’ rigorous selection process, which includes an initial eligibility screening conducted by a panel of industry experts assessing criteria such as innovation, leadership, and social responsibility, followed by a deeper evaluation of shortlisted candidates using the Rasch model. The Rasch model is a psychometric framework that produces a linear measurement scale, enabling precise comparisons across applicants who demonstrate excellence in different areas, and Treviño scored at the highest level across every evaluated dimension in the Innovation category. The results of that assessment reflect the depth and the breadth of his contributions to reconstructive surgery and patient access.

His memberships cover some of the most prominent bodies in global surgery, including the American College of Surgeons, the American Society of Plastic Surgeons, the International Society of Aesthetic Plastic Surgery, and the Federación Ibero Latinoamericana de Cirugía Plástica, among others, reflecting consistent engagement with the international surgical community. These affiliations point to a career built on standards of clinical and scientific rigor that extend well beyond any single procedure or publication. Alex Sterling, a spokesperson for Global Recognition Awards, noted that “Dr. Juan Jose Ruiz Treviño represents exactly the kind of innovator this award was created to recognize. He identified a systemic problem in patient access, developed a reproducible solution, shared it with the broader surgical community, and backed it with published clinical evidence. That combination of innovation and human impact is genuinely exceptional.”